Literature DB >> 12566657

PD and the future: the role of PD in the overall management of ESRD.

D C Mendelssohn1.   

Abstract

Given the epidemic growth of ESRD and the high costs of dialysis therapy, there is an urgent need to define the optimal dialysis modality distribution. The factors influencing dialysis modality distribution are complex and not well understood. Based on survey results that have assessed the attitudes of nephrologists in Canada, the USA and the UK, it appears that there is underutilization of both peritoneal dialysis (PD) and home hemodialysis (HD) in these countries. Nephrologists have a positive attitude towards home therapies, and do not appear to be biased against PD. A planned approach to dialysis initiation, with active promotion of PD and home HD as the initial dialysis modality for suitable patients, would be expected to revive usage of home PD and allow for the emergence of daily home HD as a significant and exciting new modality. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12566657     DOI: 10.1159/000067853

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  4 in total

1.  Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?

Authors:  James B Wetmore; Sally K Rigler; Jonathan D Mahnken; Purna Mukhopadhyay; Theresa I Shireman
Journal:  Nephrol Dial Transplant       Date:  2009-09-07       Impact factor: 5.992

2.  Attitudes and perceptions of nephrology nurses towards dialysis modality selection: a survey study.

Authors:  Karthik K Tennankore; Jay Hingwala; Diane Watson; Joanne M Bargman; Christopher T Chan
Journal:  BMC Nephrol       Date:  2013-09-10       Impact factor: 2.388

3.  The best dialysis therapy? Results from an international survey among nephrology professionals.

Authors:  Ingrid Ledebo; Claudio Ronco
Journal:  NDT Plus       Date:  2008-09-12

4.  Inhibition of the H3K4 methyltransferase SET7/9 ameliorates peritoneal fibrosis.

Authors:  Ryo Tamura; Shigehiro Doi; Ayumu Nakashima; Kensuke Sasaki; Kazuya Maeda; Toshinori Ueno; Takao Masaki
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.